Editorial: Therapeutic targeting of splicing variants in cancer

Front Pharmacol. 2023 May 5:14:1206342. doi: 10.3389/fphar.2023.1206342. eCollection 2023.

Pouya Sarvari¹, Karla Rubio^{2

3}, Stephanie Dobersch⁴, Aglaia Ntokou^{5

6}, Verónica Vallejo-Ruiz⁷

¹ Independent Researcher, Puebla, Mexico.
² International Laboratory EPIGEN, Consejo de Ciencia y Tecnología del Estado de Puebla (CONCYTEP), Instituto de Ciencias, Benemérita Universidad Autónoma de Puebla (BUAP), Puebla, Mexico.
³ Laboratoire IMoPA, Université de Lorraine, CNRS, UMR 7365, Nancy, France.
⁴ Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.
⁵ Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, New Haven, CT, United States.
⁶ Yale Department of Genetics, New Haven, CT, United States.
⁷ Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Puebla, Mexico.

No abstract available

Keywords: aberrant splicing; alternative splicing; pre-mRNA; spliceosome; splicing factors.

Publication types